👤 Xiang-Ping Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jingwen Li, Jiajia Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Jianyu Li, Wanxin Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Yan-Xue Li, Qingchao Li, Xikun Li, Enhong Li, Guobin Li, Hong-Tao Li, Xiangnan Li, Yong-Jun Li, Hang Li, Xihao Li, Ziming Li, Rongqing Li, Jing-Ming Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Yicun Li, Xiao-Lin Li, Jiajie Li, Shunqin Li, Zhao-Yang Li, K-L Li, Xinjia Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Peiwu Li, Youran Li, Yongmei Li, Changyu Li, Ran Li, X Y Li, Peilin Li, Chunshan Li, Yixiang Li, Ming Zhou Li, Guanglve Li, Ye Li, Z Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shisheng Li, Shengxu Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Dongmei Li, Yulong Li, Ru-Hao Li, Lanzhou Li, Zhi-Peng Li, Tingsong Li, Binjun Li, Chen Li, Yawei Li, Jiayang Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Wenzhe Li, Siming Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, Dongfeng Li, You Li, Xuelin Li, Fa-Hui Li, Xueyang Li, Caiyu Li, Zhen-Yuan Li, Guangpu Li, Teng Li, Wen-Jie Li, Hegen Li, Ang Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Bao Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Mingxu Li, Chen-Xi Li, Panlong Li, Changwei Li, Dejun Li, Biyu Li, Yufeng Li, Miaoxin Li, San-Feng Li, Yaoqi Li, Hu Li, Bei Li, W H Li, Sha Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Xiaoqing Li, Jinlin Li, Linke Li, C Y Li, Shuaicheng Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Yongnan Li, Maolin Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Zhongxuan Li, Xuewen Li, R Li, Xianlong Li, Aixin Li, Linting Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Hujie Li, Baohong Li, Yue-Ming Li, Shuyuan Li, L Li, Zhaohan Li, Yuanmei Li, Alexander Li, Yanwu Li, Hualing Li, Wen-juan Li, Sibing Li, Xining Li, Qinghe Li, Pilong Li, Yun-Peng Li, C X Li, Zonghua Li, Huanan Li, Jingya Li, Liqin Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wei Li, Wen-Ying Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Ming Li, Kangli Li, Runwen Li, Wenbo Li, Yarong Li, Side Li, S E Li, Timmy Li, Weidong Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Chuan-Hai Li, Lingxi Li, Jiezhen Li, Qiuya Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Zhongyu Li, Qin Li, Deyu Li, Zhen-Yu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Xiao Li, Junping Li, Qintong Li, PeiQi Li, Xiaobing Li, Naishi Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Shengchao A Li, Pan Li, Jiaying Li, Jun-Jie Li, Ruonan Li, Cui-lan Li, Shuhao Li, Ruitong Li, Huiqiong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Xue Cheng Li, Ya-Jun Li, Wenyong Li, Ding-Biao Li, Tianjun Li, Desen Li, Yansong Li, Xiying Li, Zihao Li, Weiyong Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Jianglin Li, Yingpu Li, Jing-Yao Li, Yan-Hua Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, Wan Jie Li, L K Li, Ya-Ting Li, Dongbiao Li, Aimin Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, L-Y Li, Xiuqi Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Yuancong Li, Da Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Haipeng Li, Demin Li, Chuan Li, Ze-An Li, Changhong Li, Jianmin Li, Yvonne Li, Yu Li, Minhui Li, Yiwei Li, Jiayuan Li, Xiangzhe Li, Zhichao Li, Yige Li, Siguang Li, Minglun Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chiyang Li, Chunlan Li, Hulun Li, Juan-Juan Li, Hua-Zhong Li, Hailong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Jing Li, Si Li, Xiangyun Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Zijing Li, Dengke Li, Yuchuan Li, Wentao Li, Qingling Li, Rui-Han Li, Xuhong Li, Hongyun Li, Dong Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Zhenfei Li, Shupeng Li, Sha-Sha Li, Panyuan Li, Gang Li, Mengxuan Li, Ziyu Li, Zhuo Li, Hong-Wen Li, Han-Wei Li, Xiaojuan Li, Weina Li, Xiao-Hui Li, Huaiyuan Li, Dongnan Li, Rui-Fang Li, Jianzhong Li, Ji-Liang Li, Huaping Li, C H Li, Bohua Li, Pei-Ying Li, Bing Li, Huihuang Li, Yunmin Li, Shaobin Li, Yanying Li, Ronald Li, Gui Lin Li, Chenrui Li, Shi-Hong Li, Shilun Li, Xinyu Li, John Zhong Li, Song-Chao Li, Lujiao Li, Chenghong Li, Dengfeng Li, Nianfu Li, Baohua Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Jiao Li, Zhimei Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, De-Tao Li, Chunting Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Yan-Yan Li, Liwei Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Lijun Li, Supeng Li, Hening Li, Yiju Li, Yuanhe Li, Fengxia Li, Guangxiao Li, Peixin Li, Xueqin Li, Feng-Feng Li, Jialing Li, Zu-Ling Li, Xin Li, Yunjiu Li, Dayong Li, Zonghong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chunxia Li, Chaochen Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Yali Li, Zhaoshui Li, Yu-Hui Li, Wenjing Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Kaiyuan Li, Mangmang Li, Zengyang Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, MengGe Li, Xuezhong Li, Anan Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Ning Li, Ruobing Li, Wan-Xin Li, Yanxi Li, Meitao Li, Xia Li, Yongjing Li, Ziqiang Li, Huayao Li, Wen-Xi Li, Shenghao Li, Boxuan Li, Huixue Li, Jiqing Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Zhigang Li, Yuqing Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Hongyu Li, Min-Rui Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Mengxia Li, Conglin Li, Jutang Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Zhen-Hua Li, Yiliang Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Mi Li, Youming Li, Qingrun Li, Dong-Yun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Yumiao Li, Fengfeng Li, Qinggang Li, Jiexi Li, Huixia Li, Kecheng Li, Xiangjun Li, Junxu Li, Xingye Li, Junya Li, Huiying Li, Jiang Li, Shengxian Li, Yuxi Li, Qingyang Li, Xiao-Dong Li, Chenxuan Li, Xinghuan Li, Zhaoping Li, Xingyu Li, Zhenlu Li, Xiaolei Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Cheung Li, Zhenhui Li, Zhenming Li, Xuelian Li, Shu-Fen Li, Chunjun Li, Changyan Li, Mulin Jun Li, Yinghua Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Siyu Li, Chaoying Li, Qiu Li, Juanjuan Li, Xiangyan Li, Guangzhen Li, Kunlun Li, Xiaoyu Li, Shiyun Li, Yaobo Li, Shiquan Li, Mei Li, Xuewang Li, Xiangdong Li, Jifang Li, Zhenjia Li, Manjiang Li, Wan Li, Zhizhong Li, Ding Yang Li, Xiaoya Li, Xiao-Li Li, Shan Li, Shitao Li, Lijia Li, Zehan Li, Huiliang Li, Chunqiong Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Wenxi Li, Weining Li, Wu-Jun Li, Chang-hai Li, Yuqiu Li, Bin-Kui Li, Yumao Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Xiang-Jun Li, Hongyi Li, Y X Li, Chia Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Xiancheng Li, Man-Zhi Li, Yanmei Li, De-Jun Li, Junxian Li, Keqing Li, Zhihua Li, Shuwen Li, Danxi Li, Saijuan Li, Minqi Li, Lingjun Li, Mimi Li, Si-Xing Li, Deheng Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Gao-Fei Li, Minghao Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Chanjuan Li, Nan-Nan Li, Hongming Li, Lan-Lan Li, Shuang Li, Yanchuan Li, Lingyi Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Jinglin Li, Dongyang Li, Mingfang Li, Honglong Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Jianing Li, Hanbo Li, Dingshan Li, Yinggao Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Jin-Jiang Li, Cheng-Tian Li, Chang Li, Zhi-Xing Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Xuesong Li, Zhaosha Li, Jiwei Li, Chun-Quan Li, Yongzhen Li, Weifeng Li, Tao Li, Wenhui Li, Sichen Li, Xiankai Li, Qingsheng Li, Yaxuan Li, Liangji Li, Lixiang Li, Yuchan Li, Tian-wang Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, You Ran Li, Xiaoqiong Li, Guanyu Li, Jinlan Li, Yixiao Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Sujing Li, Yuhua Li, Xuri Li, Wenzhuo Li, Y Li, Deqiang Li, Caixia Li, Zipeng Li, Mingyue Li, Hongli Li, Yun Li, Mengqiu Li, Ling-Ling Li, Yaqin Li, Yanfeng Li, Yu-He Li, Shasha Li, Xi Li, S-C Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Ziyang Li, Sitao Li, Qian Li, Yaochen Li, Tinghua Li, Zhenfen Li, Wenyang Li, Bohao Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Shuai Li, Anqi Li, Bingsong Li, Xiaoju Li, Ting Li, Zhenyu Li, Xiaonan Li, Duan Li, Xiang-Yu Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Xunjia Li, Yanchang Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, Zong-Xue Li, En-Min Li, Chunya Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Min-jun Li, Jinhua Li, Yuanheng Li, Qian-Qian Li, Chunxiao Li, Wenli Li, Shijun Li, Mengze Li, Kuan Li, Baoguang Li, Kaiwei Li, Jie-Shou Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Junxin Li, Yu-Sheng Li, Wei-Jun Li, Guoyan Li, Fei-Lin Li, Junjie Li, Nuomin Li, Shanglai Li, Yanyan Li, Shulin Li, Yue Li, Taibo Li, Junqin Li, Xueying Li, Jun-Ru Li, Zhongcai Li, JunBo Li, Zhaobing Li, Xiaoqi Li, Xiucui Li, Linxin Li, Haihua Li, Yu-Lin Li, Jen-Ming Li, Shujing Li, Tsai-Kun Li, Chen-Chen Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Shihong Li, Ya-Pei Li, Huifeng Li, Rulin Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Long Li, Shuangshuang Li, Wenjia Li, Min-Dian Li, Xiatian Li, Ding-Jian Li, Hongwei Li, Danni Li, Yangxue Li, Xiao-Qiang Li, Chengnan Li, Chuanyin Li, Min Li, Pengyang Li, Zhenzhou Li, Yiqiang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Zesong Li, Yutong Li, Xiangpan Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Boru Li, Yinxiong Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Changhui Li, Jiafei Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Shu-Fang Li, Huang Li, Qiusheng Li, Juxue Li, Man Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Gongda Li, Nan Li, Wei-Ping Li, Yajun Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Suping Li, Long Shan Li, Yanze Li, Jason Li, Xiao-Feng Li, W Li, Monica M Li, Fengjuan Li, Xianlun Li, Qi Li, Hainan Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Xionghui Li, Fei Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Hongmei Li, Kang Li, Peilong Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Wenhong Li, Quanpeng Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Wen-Ting Li, Guohua Li, Kezhen Li, Guoping Li, Xingxing Li, Ellen Li, A Li, Simin Li, Xue-Nan Li, Weiguo Li, Yijie Li, Xiaoying Li, Shengsheng Li, Suwei Li, Shuyu D Li, Jiandong Li, Ruiwen Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Jianang Li, Xue-Peng Li, Qing Li, Jiaping Li, Sheng-Tien Li, Yazhou Li, Shihao Li, Jun-Ling Li, Caesar Z Li, Weiyang Li, Feng Li, Peihong Li, Lang Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Xinxiu Li, Kaibo Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Shaodan Li, Meng-Hua Li, Yongzheng Li, J T Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Mo Li, Yueguo Li, Zheng Li, Donghe Li, Ming-Hao Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Menghua Li, Jingqi Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Chong Li, Xiao-Kang Li, Hanqi Li, Fugen Li, Yangyang Li, Yuwei Li, Dongfang Li, Xiaochen Li, Zhuorong Li, Zizhuo Li, X-H Li, Xianrui Li, Lan-Juan Li, Dong Sheng Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Xiaoman Li, Bing-Heng Li, Huanqiu Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Jinhui Li, Zhifei Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Jinku Li, Longyu Li, Guiying Li, X B Li, Changgui Li, Cuiling Li, Zhisheng Li, Xuekun Li, Yuguang Li, Wenke Li, Jiayi Li, Jianguo Li, En Li, Ximei Li, Shaoyong Li, Kai-Wen Li, Suwen Li, Peihua Li, Chang-Ping Li, Guangda Li, Yixue Li, Guandu Li, Junfeng Li, Xin-Chang Li, Jieming Li, Kongdong Li, Yue-Ying Li, Chunhui Li, Peiyu Li, Tongyao Li, Lian Li, Linfeng Li, Yuzhe Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Chang-Yan Li, Qifang Li, Xiaohua Li, Vivian Li, Duanxiang Li, Xiaolin Li, Meiting Li, Justin Li, Xue-Er Li, Zhuangzhuang Li, Xiaohui Li, Hongchang Li, Cang Li, Xuepeng Li, Mingjiang Li, Youwei Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Zongyu Li, Luquan Li, Jianyong Li, Shujie Li, Guoxing Li, Zongchao Li, Yanbin Li, Jia Li, Shiliang Li, Haimin Li, Sheng-Qing Li, Qinrui Li, Yiming Li, Xiao-Tong Li, Lingjie Li, Yiwen Li, Tie Li, Baoqi Li, Wei-Bo Li, Leyao Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Minzhe Li, Wenfeng Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Jin Li, Shibo Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, Hui Li, AnHai Li, Chenli Li, Rumei Li, Zhengrui Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Qinghua Li, Lipeng Li, Qinqin Li, Leilei Li, Ranchang Li, Defu Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Rongling Li, Zhu Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Guangqiang Li, Jian'an Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Meiyan Li, Qing-Min Li, Yonghe Li, Yun-Da Li, Xinwei Li, Shunhua Li, Yu-I Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Shen Li, Ziqi Li, Tianjiao Li, Shufen Li, Gui-Rong Li, Yunfeng Li, Yunpeng Li, Yueqi Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Zhibin Li, Yaxiong Li, Zhenli Li, Qing-Fang Li, Rosa J W Li, Yunxiao Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhi Li, Zhankui Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Taixu Li, Mingzhou Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Zhijie Li, Meng Li, Cun Li, Huimin Li, T Li, Ruifang Li, Xiao-xu Li, Man-Xiang Li, Yinghui Li, Cong Li, Chengbin Li, Feilong Li, Sin-Lun Li, Yuping Li, Mengfan Li, Weiling Li, Jie Li, Shiyan Li, Lianbing Li, G Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Jialin Li, Wenjian Li, He Li, Bichun Li, Hanqin Li, Xiong Bing Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Chaojie Li, Michelle Li, Caolong Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Guangdi Li, Peipei Li, Tian-Yi Li, Xiaxia Li, Yuefeng Li, Nien Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Lin Li, Jieshou Li, Chenjie Li, Jinfang Li, Roger Li, Yanming Li, Hong-Lan Li, Mengqing Li, Ben-Shang Li, S L Li, Ming-Kai Li, Shunqing Li, Xionghao Li, Lan Li, Menglu Li, Huiqing Li, Yantao Li, Yanwei Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Ruolin Li, Yongle Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Muzi Li, Yong-Liang Li, Gen Li, Dong-Ling Li, M Li, Chenwen Li, Jiehan Li, Le Li, Hongguo Li, Yong-Jian Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Si-Wei Li, Ai-Qin Li, Zichao Li, Manru Li, Caili Li, Yingxi Li, Yuqian Li, Guannan Li, Wei-Dong Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Wenlong Li, Ya-Feng Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Xudong Li, Guoxi Li, Xingfang Li, Shugang Li, Shengli Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Ru Li, Yongxin Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Bingbing Li, Qinglin Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, Zhenyan Li, H J Li, Yanping Li, Ji Xia Li, Yu-Ye Li, Meizi Li, Qing-Wei Li, Qiang Li, Yuezheng Li, Hsiao-Hui Li, L I Li, Zhengnan Li, Jianglong Li, Hongzheng Li, Laiqing Li, Ningyang Li, Zhongxia Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Guojun Li, Xuefei Li, Senlin Li, Hung Li, Jinping Li, Huili Li, Sainan Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Hongzhe K Li, Fulun Li, Xiao-Qiu Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Zhihui Li, Yi-Yang Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Shichao Li, Gan Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Lihong Li, Chun Li, Jianan Li, Wenfang Li, Haixia Li, Xiangling Li, Sung-Chou Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Shuang-Ling Li, Zhong Li, Xiao-Long Li, Hung-Yuan Li, Xiaofei Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, H Li, Xiaojiao Li, Dongliang Li, Chenxiao Li, Yinzhen Li, Hongjia Li, Yunsheng Li, Xiao-Jing Li, Li-Min Li, Xiangqi Li, Jian Li, Y H Li, Jia-Peng Li, Daoyuan Li, Baichuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Jian-Mei Li, Xiao-Jun Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Qiao Li, Xueling Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Yike Li, Wanni Li, Yihan Li, Chitao Li, Haiyang Li, Junsheng Li, Jiayu Li, Xiaobai Li, Pingping Li, Mingquan Li, Wen-Ya Li, Suran Li, Rongxia Li, Yunlun Li, Yuanfang Li, Yingqin Li, Guoqin Li, Qiner Li, Huiqin Li, Shanhang Li, Jiafang Li, Chunlin Li, Han-Bing Li, Zongzhe Li, Yikang Li, Jisen Li, Si-Yuan Li, Caihong Li, Hongmin Li, Yajing Li, Peng Peng Li, Guanglu Li, Kenli Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Jian-Shuang Li, Xinxin Li, You-Mei Li, Chenglan Li, Dazhi Li, Yubin Li, Yuhong Li, Beixu Li, Fengqiao Li, Guiyuan Li, Di Li, Yanbing Li, Suk-Yee Li, Shengjie Li, Yuanyuan Li, Jufang Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Jun Li, Minghua Li, Xiyue Li, Zhuoran Li, Tianchang Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Yingjian Li, Hongjuan Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Wen-Chao Li, Dan-Ni Li, Sunan Li, Zhencong Li, Chunqing Li, Lai K Li, Jiong Li, Yanni Li, Daiyue Li, Bingong Li, Huifang Li, Xiujuan Li, Yongsheng Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Ding Li, Yuling Li, Wendeng Li, Yetian Li, Xianlin Li, Chuangpeng Li, Mingrui Li, Linyan Li, Yanjun Li, Shengze Li, Ming-Yang Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Congcong Li, Ji-Lin Li, Ping'an Li, Yushan Li, Juan Li, Huan Li, Weiping Li, Changjiang Li, Chengping Li, G-P Li, He-Zhen Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Yinliang Li, Jinfeng Li, Wen Li, Shiheng Li, Jiangan Li, Hsiao-Fen Li, Yu-Kun Li, Weihai Li, Zhaojin Li, Mengjiao Li, Bingxin Li, Wenjuan Li, Chia-Yang Li, Wenyu Li, Meng-Meng Li, Tianxiang Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Xi-Xi Li, Wenlei Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Haiyan Li, Ming D Li, Chenguang Li, Ruyue Li, Xujun Li, Chi-Ming Li, Xiaolian Li, Yi-Ning Li, Dandan Li, Yunan Li, Jiazhou Li, Sherly X Li, Zechuan Li, Zhijun Li, Ya-Ge Li, Wanling Li, Yinyan Li, Qijun Li, Guangli Li, Rujia Li, Zhiwei Li, Lixia Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Xiaohan Li, Wan-Shan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Jing-gao Li, Yiyang Li, Xuejun Li, Fengxiang Li, Nana Li, Shunwang Li, Chao Li, Yaqing Li, Bingsheng Li, Yaqiao Li, Jingui Li, Huamao Li, Xiankun Li, Jingke Li, Xiaowei Li, Tianyao Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Hai-Yun Li, Haoran Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Zhixiong Li, Chumei Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Jialun Li, Xinjian Li, Rui Li, Zilu Li, Xuemin Li, Zezhi Li, Sheng-Fu Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Binghua Li, Xuyi Li, Hanjun Li, Yunchu Li, Jin-Qiu Li, Qihua Li, Zhengyao Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Lin-Feng Li, Xutong Li, Ranwei Li, Kai Li, Ziqing Li, Keanning Li, Wei-Li Li, Shuangxiu Li, Yongjin Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Luyao Li, Chun-Xu Li, Weike Li, Desheng Li, Zhixuan Li, Long-Yan Li, Chuanbao Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Hengtong Li, Ling-Zhi Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Bolun Li, Kunlin Li, Linchuan Li, Jiachen Li, Haibin Li, Shu-Qi Li, Zehua Li, Huangbao Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Congye Li, Xinrui Li, Wensheng Li, Dehai Li, Jiannan Li, Qingshang Li, Guanbin Li, Hanbin Li, Zhiyi Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Mingke Li, Suchun Li, Huanhuan Li, Xiaoyuan Li, Yanan Li, Zongfang Li, Yang Li, Jiayan Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Dongdong Li, Yimei Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Yilong Li, Lihua Li, Xue-Lian Li, Yan-Li Li, Zhiping Li, Haiming Li, Yansen Li, Gaijie Li, Yanli Li, Jingfeng Li, Zhi-Yuan Li, Yuemei Li, Hai Li, Kaibin Li, Yuan-Jing Li, Xuefeng Li, Xiaohu Li, Wenjie Li, Ruikai Li, Mengjuan Li, Xiao-Hong Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Baosheng Li, Zhonglian Li, Yujun Li, Mian Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Guojin Li, Yueting Li, Xin-Yue Li, YaJie Li, Dingchen Li, Xiaoling Li, Yanqing Li, Zijian Li, Jixuan Li, Zhandong Li, Xuejie Li, Meng-Jun Li, Congjiao Li, Peining Li, Gaizhen Li, Huilin Li, Liang Li, Songtao Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Chenlu Li, Keshen Li, Kechun Li, Nianyu Li, Yuxin Li, Shaoliang Li, X-L Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Qun Li, Dongye Li, Tianye Li, Cuiguang Li, Zhen Li, Yuan Li, F Li, Chunhong Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Tiewei Li, Bing-Hui Li, Rong-Bing Li, Daniel Tian Li, Jingyong Li, Honggang Li, Rong Li, Shikang Li, Wei-Yang Li, Mingkun Li, Binxing Li, Shi-Ying Li, Ming Xing Li, Zixiao Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Hong-Lian Li, Bei-Bei Li, Shishi Li, Xiumei Li, Haitong Li, Ruibing Li, Melody M H Li, Yuli Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Baoting Li, Longxuan Li, Huiyou Li, Ka Wan Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Yu-Hao Li, Gui-xing Li, Shunle Li, Shilin Li, Niu Li, Siyue Li, Diyan Li, Shili Li, Mengyao Li, Yixuan Li, Shan-Shan Li, Zhuanjian Li, Meiqing Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Zonglin Li, Yinhao Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Junhong Li, Youchen Li, Li Li, W Y Li, Hanxue Li, Lulu Li, Yi-Heng Li, L P Li, Xiaoqin Li, Runbing Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Jingyi Li, Ji-Cheng Li, Yuxiang Li, Hao-Fei Li, Haolong Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Haiyu Li, Huijuan Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Guohui Li, Kainan Li, Yongzhe Li, Qingfeng Li, Xiaoyan Li, Tianyi Li, Nanlong Li, Ping Li, Xu-Bo Li, Nien-Chen Li, Fangzhou Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Biao Li, Yuanchuang Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Hongliang Li, Qing-Chang Li, Hong-Yan Li, Shengbiao Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Dengxiong Li, Xiaomin Li, Sijie Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Qiuyan Li, Zhouxiang Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Chunjie Li, Yixi Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Junyi Li, Kaiyi Li, Wenqun Li, Dongtao Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Zuo-Lin Li, Chenxi Li, Yuanjing Li, Zhengwei Li, Linqi Li, Xixi Li, Bingjue Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Zhenguang Li, Xiaotian Li, Jia-Ru Li, Shuhui Li, Shu-Hong Li, Chun-Xiao Li, Pei-Qin Li, Shuyue Li, Mengying Li, Fangyan Li, Tongzheng Li, Quan-Zhong Li, Yihong Li, Yaxian Li, Duo Li, Dali Li, Zhiming Li, Xuemei Li, Hongxia Li, Yongting Li, Xueting Li, Danyang Li, Zhenjun Li, Ren Li, Tiandong Li, Lanfang Li, Hongye Li, Mingwei Li, Di-Jie Li, Bo Li, Jinliang Li, Wenxin Li, Qiji Li, W J Li, Zhipeng Li, Zhijia Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaobo Li, Xiaoting Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Xiao-Yao Li, Kun-Ping Li, Weirong Li, Weihua Li, Shangming Li, Yibo Li, Yaqi Li, Gui-Hua Li, Zhihong Li, Yandong Li, Runzhao Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Xiufeng Li, Yingjun Li, Yanxin Li, Xiaohuan Li, Boya Li, Ying-Qin Li, Lamei Li, O Li, Fan Li, Jun Z Li, Suheng Li, Joyce Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Junru Li, Zhiqiang Li, Hecheng Li, Jiangchao Li, Haifeng Li, Changkai Li, Yueping Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Xuanxuan Li, Rui-Jún Eveline Li, Bing-Mei Li, Yunman Li, Chaoqian Li, Shuhua Li, Yu-Cheng Li, Yirun Li, Chunying Li, Haomiao Li, Weiheng Li, Leipeng Li, Qianqian Li, Baizhou Li, Zhengliang Li, YiQing Li, Han-Ru Li, Wei-Qin Li, Sheng Li, Weijie Li, Guoyin Li, Yaqiang Li, Qingxian Li, Zongyi Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Yongpeng Li, Chengjun Li, Keke Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Ji Li, Huaying Li, Tuojian Li, Yixin Li, Ziyue Li, Juntong Li, Zhongzhe Li, Xiang Li, Yumei Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Shaomin Li, Heying Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shuying Li, Shibao Li, Pengjie Li, Xiaomei Li, Ruijin Li, Kunlong Li
articles
Chunbin Sun, Shuang Sha, Yubang Shan +5 more · 2025 · International journal of nanomedicine · added 2026-04-24
Alzheimer's disease (AD) is a common progressive and irreversible neurodegenerative disease. AD accounts for 60%-70% of all dementia cases, ranking as the seventh leading cause of death globally. Huma Show more
Alzheimer's disease (AD) is a common progressive and irreversible neurodegenerative disease. AD accounts for 60%-70% of all dementia cases, ranking as the seventh leading cause of death globally. Human umbilical cord mesenchymal stem cells (hUC-MSCs) characterized by their abundant availability and low immunogenicity, have demonstrated significant therapeutic potential for AD in both preclinical studies and clinical trials. The use of exosomes can help mitigate the issues associated with cellular therapies. However, the clinical application of hUC-MSCs remains challenging due to their inability to effectively traverse the blood-brain barrier (BBB) and reach pathological sites. Therapeutic strategies utilizing exosomes derived from hUC-MSCs (Exos) have emerged as an effective approach for AD intervention. Here, we used ultrasound to construct multifunctional Exos (MsEVB@R/siRNA) for AD therapy. We obtained small interfering RNA for β-site precursor protein lyase-1 (BACE1 siRNA) and berberine for co-delivery into the brain. Berberine, a classical anti-inflammatory agent, effectively alleviates neuroinflammation in AD pathogenesis. BACE1 serves as the pivotal cleavage enzyme in amyloid β-protein (Aβ) formation, where silencing BACE1 synthesis through BACE1 siRNA significantly reduces Aβ production. In a 5xFAD mouse model, Exos selectively targeted microglial and neuronal cells after nasal delivery under the action of neural cell-targeting peptide rabies virus glycoprotein 29 (RVG29). BACE1 siRNA and berberine (BBR) loading enhanced the effectiveness of Exos in improving cognitive function, promoting nerve repair and regeneration, reducing inflammatory cytokine expression, and suppressing glial responses. BACE1 siRNA release was confirmed to reduce BACE1 expression and Aβ deposition. Concurrently, berberine effectively suppressed the release of inflammatory factors, thereby reducing neuroinflammation. In conclusion, the nasal delivery of engineered exosomes is a potentially effective method for treating AD. Show less
📄 PDF DOI: 10.2147/IJN.S506793
BACE1
Xiaokun Li, Zhiheng Rao, Wenhao Hu +2 more · 2025 · Obesity reviews : an official journal of the International Association for the Study of Obesity · Blackwell Publishing · added 2026-04-24
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, e Show more
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, excess deposition of lipids in hepatic lipid droplets. Despite the growing prevalence and serious risks it poses, including liver decompensation, the need for transplantation, and increased patient mortality, MASH currently faces no approved pharmacotherapy. Several promising treatment candidates have emerged from recent clinical trials, including analogs of FGF21 and agonists of the associated FGFR1-KLB complex. These agents were well-tolerated in trials and have demonstrated significant improvements in both histological and biochemical markers of liver fat content, inflammation, injury, and fibrosis in patients with MASH. Endocrine FGF21 plays a vital role in maintaining homeostasis of lipid, glucose, and energy metabolism. It achieves this through pathways that target lipids or lipid droplets in adipocytes and hepatocytes. Mechanistically, pharmacological FGF21 acts as a potent catabolic factor to promote lipid or lipid droplet lipolysis, fatty acid oxidation, mitochondrial catabolic flux, and heat-dissipating energy expenditure, leading to effective clearance of hepatic and systemic gluco-lipotoxicity and inflammatory stress, thereby preventing obesity, diabetes, and MASH pathologies. In this review, we aim to provide an update on the outcomes of clinical trials for several FGF21 mimetics. We compare these outcomes with preclinical studies and offer a lipid-centric perspective on the mechanisms underlying the clinical benefits of these agents for MASH. Show less
no PDF DOI: 10.1111/obr.13861
FGFR1
Jimmy H Mo, Chao Zhai, Kwangsek Jung +4 more · 2025 · iScience · Elsevier · added 2026-04-24
Vitellogenin is thought to share a common ancestor with human apolipoprotein B (ApoB) for systemic lipid transport. In
📄 PDF DOI: 10.1016/j.isci.2025.111860
APOB
Hui Wang, Timothy S Chang, Beth A Dombroski +64 more · 2025 · Movement disorders : official journal of the Movement Disorder Society · Wiley · added 2026-04-24
The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear pa Show more
The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP). To investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP. Utilizing whole genome sequencing data from 1684 PSP cases and 2392 controls, the three large CNVs (α, β, and γ) and structural forms within 17q21.31 were identified and analyzed for their association with PSP. We found that the copy number of γ was associated with increased PSP risk (odds ratio [OR] = 1.10, P = 0.0018). From H1β1γ1 (OR = 1.21) and H1β2γ1 (OR = 1.24) to H1β1γ4 (OR = 1.57), structural forms of H1 with additional copies of γ displayed a higher risk for PSP. The frequency of the risk sub-haplotype H1c rises from 1% in individuals with two γ copies to 88% in those with eight copies. Additionally, γ duplication up-regulates expression of ARL17B, LRRC37A/LRRC37A2, and NSFP1, while down-regulating KANSL1. Single-nucleus RNA-seq of the dorsolateral prefrontal cortex analysis reveals γ duplication primarily up-regulates LRRC37A/LRRC37A2 in neuronal cells. The copy number of γ is associated with the risk of PSP after adjusting for H1/H2, indicating that the complex structure at 17q21.31 is an important consideration when evaluating the genetic risk of PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Show less
📄 PDF DOI: 10.1002/mds.30150
KANSL1
Wenyong Li, Rudi Lv, Husong Su +4 more · 2025 · Scientific reports · Nature · added 2026-04-24
The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell deat Show more
The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell death. The epithelial-to-mesenchymal transition (EMT) provides malignant cells with the adaptability and movement necessary for tumor advancement and spread, with zinc finger E-box binding homeobox 1(ZEB1) playing a pivotal role as a transcriptional factor in EMT. This investigation initially examined the association between the KLF15 protein and EMT associated transcription factors such as ZEB1, Slug, and Snail, along with marker proteins like E-cadherin and β-catenin in bladder cancer. Furthermore, we explored their connections with clinicopathological attributes and conducted prognostic analyses. Immunohistochemical techniques were utilized to ascertain the presence of KLF15 protein and EMT-associated transcription factor proteins, along with their marker proteins in 110 specimens of bladder cancer tissues. Concurrently, clinicopathological data and postoperative survival statistics were amassed. The rates of KLF15 and Slug protein expression were linked with pathological differentiation, lymphatic involvement, and pTNM staging. The protein expression rates of ZEB1, Slug, Snail, E-cadherin, and β-catenin also showed associations with lymphatic metastasis and pTNM stages. Notably, the expression of KLF15, the coexpression of KLF15 and ZEB1, and lymphatic metastasis emerged as independent prognostic indicators for the overall survival rates in bladder cancer cases. EMT enhances the risk of tumor recurrence and reduces overall survival durations in bladder cancer cases. Furthermore, KLF15 is a significant contributor to the EMT pathway in bladder cancer, primarily through its interaction with the transcription factor ZEB1. KLF15 and ZEB1 might serve as key biomarkers for metastasis and prognosis, offering potential new targets for therapeutic intervention in bladder cancer. Show less
no PDF DOI: 10.1038/s41598-025-22698-5
SNAI1
Litong Qi, Hua Shen, Meng Chai +11 more · 2025 · Cardiovascular diabetology · BioMed Central · added 2026-04-24
This study evaluated the efficacy and safety of tafolecimab in patients with type 2 diabetes (T2D) and hypercholesterolemia by a post-hoc analysis of pooled data from three phase 3 trials. Data from u Show more
This study evaluated the efficacy and safety of tafolecimab in patients with type 2 diabetes (T2D) and hypercholesterolemia by a post-hoc analysis of pooled data from three phase 3 trials. Data from up to 12 weeks were analyzed to assess the effects of tafolecimab 450 mg every four weeks (Q4W) in patients with T2D and hypercholesterolemia. The primary endpoint was the percentage change in low-density lipoprotein cholesterol (LDL-C) levels from baseline to week 12. Secondary endpoints included the proportion of participants achieving LDL-C levels below 1.8 mmol/L at weeks 12, the proportion of patients achieving LDL-C ≥ 50% reduction and LDL-C < 1.4 mmol/L, as well as percentage changes from baseline to week 12 in non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apo B), lipoprotein(a) [Lp(a)], and triglyceride (TG) levels. The reduction in LDL-C from baseline was significantly greater in patients receiving tafolecimab than in those receiving placebo (estimated treatment difference: - 64.02%, 95% confidence interval: [- 68.08%, - 59.96%], P < 0.0001). The proportion of patients achieving a reduction of over 50% and an absolute LDL-C value below 1.4 mmol/L was significantly higher in the tafolecimab group than that in the placebo group (P < 0.0001). Furthermore, a significantly greater proportion of patients in the tafolecimab group achieved LDL-C levels below 1.8 mmol/L at week 12 compared to the placebo group (P < 0.0001). The tafolecimab group also showed significant reductions in TG, non-HDL-C, apo B, and Lp(a) from baseline to week 12 compared to the placebo group (all P < 0.001). The incidence of adverse events was generally similar between the two groups. Tafolecimab 450 mg Q4W demonstrated a superior lipid-lowering efficacy and favorable safety profile compared to placebo. This suggests it could be a promising new treatment option for Chinese patients with T2D and hypercholesterolemia. Show less
📄 PDF DOI: 10.1186/s12933-025-02816-3
APOB
Yixuan Han, Suli Wang, Chenyang Li +8 more · 2025 · International immunopharmacology · Elsevier · added 2026-04-24
Interleukin-27 (IL-27), an Interleukin-12 (IL-12) family heterodimeric cytokine, plays a central yet complex role in immunoregulation within the intestinal mucosa, where its context-dependent actions Show more
Interleukin-27 (IL-27), an Interleukin-12 (IL-12) family heterodimeric cytokine, plays a central yet complex role in immunoregulation within the intestinal mucosa, where its context-dependent actions can promote both protective and pathogenic outcomes. Although its cellular sources, receptor structure (IL-27Rα/gp130 complex), and involvement in regulating key immune cells (e.g., T-cell subsets, macrophages, neutrophils) and epithelial functions are established, the precise mechanisms underlying its paradoxical effects-balancing homeostasis with inflammation-remain incompletely resolved. This review synthesizes current understanding of IL-27 biology to clarify its multifaceted role. Crucial insights into these dual functions have emerged from preclinical models, including murine colitis (e.g., DSS-, TNBS-induced), enteric infection (e.g., Toxoplasma gondii, Citrobacter rodentium), and colorectal cancer models. These studies demonstrate that IL-27 critically orchestrates gut immunity, maintaining homeostasis through antimicrobial defense and barrier enhancement while suppressing immunopathology. Conversely, its dysregulation drives chronic inflammation and carcinogenesis. Clinically, IL-27 expression correlates with disease activity in inflammatory bowel disease (IBD), colorectal cancer (CRC), and infections, highlighting its biomarker potential. Consequently, targeting the IL-27 pathway presents promising therapeutic avenues: augmenting signaling may mitigate IBD hyperinflammation, while inhibition could bolster antitumor immunity or resolve infection-driven pathology. Future research must prioritize defining context-specific IL-27 functions, optimizing delivery strategies, and integrating IL-27 targeting with existing biologics to translate its immunomodulatory potential into novel therapies for intestinal diseases. Show less
no PDF DOI: 10.1016/j.intimp.2025.115755
IL27
Jing Gan, Yuncong Wang, Zhuoran Shi +13 more · 2025 · NPJ precision oncology · Nature · added 2026-04-24
Increasing evidence underscores the driving role of coding and non-coding variants in cancer development. Analyzing gene sets in biological processes offers deeper insights into the molecular mechanis Show more
Increasing evidence underscores the driving role of coding and non-coding variants in cancer development. Analyzing gene sets in biological processes offers deeper insights into the molecular mechanisms of carcinogenesis. Here, we developed geMER to identify candidate driver genes genome-wide by detecting mutation enrichment regions within coding and non-coding elements. We subsequently designed a pipeline to identify a core driver gene set (CDGS) that broadly promotes carcinogenesis across multiple cancers. CDGS comprising 25 genes for 25 cancers displayed instability in DNA aberrations. Variants within the TTN enrichment region may influence the folding of the I-set domain by altering local polarity or side-chain chemistry properties of amino acids, potentially disrupting its antigen-binding capacity in LUAD. Multi-omics analysis revealed that APOB emerged as a candidate oncogene in LIHC, whose genetic alterations within the enrichment region may activate key TFs, upregulate DNA methylation levels, modulate critical histone modifications, and enhance transcriptional activity in the HepG2 and A549 cell lines compared to Panc1. Additionally, CDGS mutation status was an independent prognostic factor for the pan-cancer cohort. High-risk patients tended to develop an immunosuppressive microenvironment and demonstrated a higher likelihood of responding to ICI therapy. Finally, we provided a user-friendly web interface to explore candidate driver genes using geMER ( http://bio-bigdata.hrbmu.edu.cn/geMER/ ). Show less
📄 PDF DOI: 10.1038/s41698-025-01060-y
APOB
Jiahao Guo, Hao Xie, Quanting Yin +8 more · 2025 · Discover oncology · Springer · added 2026-04-24
Although studies have suggested a potential link between the nervous system and prostate cancer, the underlying regulatory mechanisms remain unclear. Therefore, it is crucial to identify the genes inv Show more
Although studies have suggested a potential link between the nervous system and prostate cancer, the underlying regulatory mechanisms remain unclear. Therefore, it is crucial to identify the genes involved in regulating prostate cancer within the nervous system. We utilized eQTL data from eight neural cell types as exposure factors and GWAS data for prostate cancer as outcome events. Mendelian randomization (MR) analyses were performed to identify causative genes associated with prostate, bladder, and renal cancers in Astrocytes, Endothelial cells, Excitatory neurons, Inhibitory neurons, Microglia, Oligodendrocytes, OPCs/COPs, and Pericytes. Bladder and renal cancers were used as controls. Sensitivity analyses (heterogeneity, pleiotropy, and leave-one-out tests) were conducted to ensure reliability. In astrocytes, seven positive genes were identified as being causally related to prostate cancer: KANSL1, AC005670.2, ARL17B, LRRC37A2, LRRC37A, MAPT, and LINC02210. In. Endothelial cells, Inhibitory neuron and Microglia, three genes (LRRC37A2, ARL17B, and KANSL1) were identified as risk genes that are associated with prostate cancer. Four protective genes were identified in excitatory neurons, including LRRC37A2, ARL17B, KANSL1 and LINC02210. In oligodendrocytes, eight genes were identified, with LRRC37A2, ARL17B, and KANSL1 acting as protective factors, while OR2L13, OR2L3, OR2L5, OR2L2, and OR2M4 were identified as risk factors. Additionally, sensitivity analyses showed no heterogeneity or horizontal pleiotropy in the MR results, confirming their reliability and stability. In addition, no positive genes were found in bladder cancer and renal cancer. Our study highlights the role of the nervous system, particularly astrocytes, in regulating prostate cancer. We identified three genes, with LRRC37A2, ARL17B, and KANSL1 emerging as key protective factors. These findings provide potential targets for prostate cancer diagnosis and treatment. The online version contains supplementary material available at 10.1007/s12672-025-03711-9. Show less
📄 PDF DOI: 10.1007/s12672-025-03711-9
KANSL1
Yang Zheng, Qiuxuan Li, Yuxiu Yang +4 more · 2025 · Journal of the American Heart Association · added 2026-04-24
Calcific aortic valve stenosis (CAVS) can lead to cardiac adverse outcomes; however, currently, no effective pharmacological interventions are available to prevent or delay disease progression. Emergi Show more
Calcific aortic valve stenosis (CAVS) can lead to cardiac adverse outcomes; however, currently, no effective pharmacological interventions are available to prevent or delay disease progression. Emerging evidence has identified significant associations between CAVS and key biomarkers, including Lp(a) (lipoprotein [a]), low-density lipoprotein cholesterol, and PCSK9 (proprotein convertase subtilisin/kexin type 9). However, robust evidence from randomized controlled trials is still lacking to substantiate these associations. The EPISODE (Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis) trial is a prospective, evaluator-blinded, randomized controlled trial designed to assess the therapeutic efficacy of PCSK9 inhibitors in patients with CAVS. A total of 160 patients with mild-to-moderate or asymptomatic severe CAVS will be randomly assigned to receive either statin monotherapy or a combination of statins and PCSK9 inhibitors. Participants will undergo follow-up assessments at 3-month intervals for 24 months, including transthoracic ultrasonic cardiogram, computed tomography, and quality-of-life evaluations using the EuroQol-5 Dimension-3 Level questionnaire. The primary end point is the annualized change in peak aortic jet velocity, whereas secondary end points encompass changes in aortic valve area, calcification score, incidence of heart valve surgery, and quality of life. Safety end points include all-cause mortality and cardiovascular events. The trial aims to evaluate the efficacy of PCSK9 inhibitors in modulating disease progression, reducing adverse cardiovascular events, and improving clinical outcomes in patients with CAVS. The anticipated findings are expected to provide critical insights for developing novel therapeutic strategies for early intervention in CAVS. URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04968509. Show less
📄 PDF DOI: 10.1161/JAHA.125.042112
LPA
Chenlu He, Zejian Li, Hao Jiang +3 more · 2025 · Advanced materials (Deerfield Beach, Fla.) · Wiley · added 2026-04-24
Halide perovskite nanomaterials have emerged as a transformative platform for generating and manipulating polarized luminescence, offering unprecedented opportunities for next-generation optoelectroni Show more
Halide perovskite nanomaterials have emerged as a transformative platform for generating and manipulating polarized luminescence, offering unprecedented opportunities for next-generation optoelectronic technologies. This review comprehensively examines recent advances in engineering both linearly polarized luminescence (LPL) and circularly polarized luminescence (CPL) from perovskite nanostructures, focusing on structural design principles, chirality transfer mechanisms, and performance optimization strategies. Methods are systematically analyzed to achieve polarized emission, including anisotropic nanocrystal growth, chiral ligand functionalization, and liquid crystal-mediated alignment, while highlighting critical optical factors such as dissymmetry factors and photoluminescence quantum yield. Key challenges in enhancing the precision control over perovskite nanostructures, room-temperature CPL efficiency, and scalable assembly are discussed, with a forward-looking perspective on the integration of artificial intelligence (AI) to accelerate progress in the development of perovskite nanomaterials with customized polarized luminescence. By bridging fundamental insights with technological applications, this review outlines a roadmap for developing perovskite-based polarized light sources that combine high performance, stability, and manufacturability, which are key enablers for the future of quantum photonics, ultra-secure communication, and intelligent optical systems. Show less
no PDF DOI: 10.1002/adma.202507400
LPL
Deepsing Syangtan, Deena Al Mahbuba, Sayaka Masuko +10 more · 2025 · Stem cell reports · Elsevier · added 2026-04-24
Heparan sulfate (HS) is an anionic polysaccharide generated by all animal cells, but our understanding of its roles in human pluripotent stem cell (hPSC) self-renewal and differentiation is limited. W Show more
Heparan sulfate (HS) is an anionic polysaccharide generated by all animal cells, but our understanding of its roles in human pluripotent stem cell (hPSC) self-renewal and differentiation is limited. We derived HS-deficient hPSCs by disrupting the EXT1 glycosyltransferase. These EXT1 Show less
📄 PDF DOI: 10.1016/j.stemcr.2024.11.014
EXT1
Sijing Liu, Caixia Yang, Xiaotong Zhou +5 more · 2025 · Journal of medicinal food · SAGE Publications · added 2026-04-24
Cordyceps has been clinically used to treat atherosclerosis (AS) since the 1980s. However, the active components responsible for its effects and the underlying mechanisms remain poorly understood. In Show more
Cordyceps has been clinically used to treat atherosclerosis (AS) since the 1980s. However, the active components responsible for its effects and the underlying mechanisms remain poorly understood. In this study, we aimed to explore the anti-AS effects and mechanisms of action of wild Cordyceps polysaccharides (WCP). The molecular weight, monosaccharide composition, and structural characteristics of WCP were analyzed. Furthermore, the anti-AS effects of WCP were evaluated using apolipoprotein E knockout ( Show less
no PDF DOI: 10.1177/1096620X251380195
NR1H3
Qian Li, Yang Ang, Qing-Qing Zhou +15 more · 2025 · Journal of pharmaceutical analysis · Elsevier · added 2026-04-24
Acute respiratory distress syndrome (ARDS) is a common respiratory emergency, but current clinical treatment remains at the level of symptomatic support and there is a lack of effective targeted treat Show more
Acute respiratory distress syndrome (ARDS) is a common respiratory emergency, but current clinical treatment remains at the level of symptomatic support and there is a lack of effective targeted treatment measures. Our previous study confirmed that inhalation of hydrogen gas can reduce the acute lung injury of ARDS, but the application of hydrogen has flammable and explosive safety concerns. Drinking hydrogen-rich liquid or inhaling hydrogen gas has been shown to play an important role in scavenging reactive oxygen species and maintaining mitochondrial quality control balance, thus improving ARDS in patients and animal models. Coral calcium hydrogenation (CCH) is a new solid molecular hydrogen carrier prepared from coral calcium (CC). Whether and how CCH affects acute lung injury in ARDS remains unstudied. In this study, we observed the therapeutic effect of CCH on lipopolysaccharide (LPS) induced acute lung injury in ARDS mice. The survival rate of mice treated with CCH and hydrogen inhalation was found to be comparable, demonstrating a significant improvement compared to the untreated ARDS model group. CCH treatment significantly reduced pulmonary hemorrhage and edema, and improved pulmonary function and local microcirculation in ARDS mice. CCH promoted mitochondrial peripheral division in the early course of ARDS by activating mitochondrial thioredoxin 2 (Trx2), improved lung mitochondrial dysfunction induced by LPS, and reduced oxidative stress damage. The results indicate that CCH is a highly efficient hydrogen-rich agent that can attenuate acute lung injury of ARDS by improving the mitochondrial function through Trx2 activation. Show less
no PDF DOI: 10.1016/j.jpha.2024.101039
MYO19
Fangbo Hu, Rongjie Wu, Xu Zhao +5 more · 2025 · Translational stroke research · Springer · added 2026-04-24
Mendelian randomization studies have identified that apolipoprotein B (ApoB) is the primary genetic determinant of ischemic stroke, rather than other lipid markers. However, its association with recur Show more
Mendelian randomization studies have identified that apolipoprotein B (ApoB) is the primary genetic determinant of ischemic stroke, rather than other lipid markers. However, its association with recurrent non-cardioembolic acute ischemic stroke (NCAIS) remains unclear. This study aimed to investigate this association. This study recruited 578 patients with acute ischemic stroke, excluding those with cardiogenic embolism. After a 3-year follow-up, a total of 428 patients completed the prospective cohort study. A Cox regression model was used to evaluate the association between ApoB levels at admission and the recurrence rate. Additionally, a nested case-control study was conducted by comparing blood samples collected at the time of recurrence from recurrent patients with those from non-recurrent patients. Binary logistic regression and ROC analysis were used to assess the association between serum ApoB, low-density lipoprotein cholesterol (LDL-C), and recurrent stroke at the time of recurrence. The Cox regression model demonstrated that ApoB levels at admission were independently associated with an increased risk of recurrent NCAIS (HR=6.697; 95%CI 2.581-17.374, P < 0.001). Recurrent stroke patients had significantly higher serum ApoB levels at admission than non-recurrent ones [0.85 g/L (IQR 0.21) vs. 0.63 g/L (IQR 0.15)]. In ROC analysis, ApoB (AUC = 0.732) showed a greater discriminatory ability for recurrent stroke than LDL-C (AUC = 0.685). Higher serum ApoB levels increased the risk of recurrence in patients with NCAIS, and ApoB demonstrated better discriminatory ability than LDL-C after therapy. These findings suggest that routine ApoB measurement may help improve secondary stroke risk assessment. Show less
📄 PDF DOI: 10.1007/s12975-025-01367-9
APOB
Xiuli Han, He Li, Yu Sun +1 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
This study investigates the effect of angiopoietin-like 4 (ANGPTL4) on allergic rhinitis (AR) and explores the underlying mechanisms. A mouse model of AR was generated through ovalbumin (OVA) challeng Show more
This study investigates the effect of angiopoietin-like 4 (ANGPTL4) on allergic rhinitis (AR) and explores the underlying mechanisms. A mouse model of AR was generated through ovalbumin (OVA) challenge. The numbers of nasal rubbing and sneezing were counted and scored. Histological staining was conducted to analyze pathological alterations and inflammation in the mouse nasal mucosa. Inflammatory cytokines in serum and nasal lavage fluid (NALF) samples were analyzed using ELISA kits. Populations of regulatory T cells (Tregs) and Th17 cells in NALF or lymph nodes were analyzed using flow cytometry. Mice with AR were administered short hairpin (sh) RNAs targeting ANGPTL4. The effect of Notch pathway in AR severity was analyzed by gain- and loss-of-function assays. The consistent OVA challenge led to significant AR-like symptoms in mice, along with increased Notch signaling activation. Inhibiting this pathway using γ-secretase inhibitor (DAPT) markedly reduced the AR scores and alleviated inflammatory infiltration by improving Treg/Th17 cell balance. ANGPTL4 silencing significantly mitigated AR-related symptoms, Treg/Th17 cell imbalance, and inflammatory cascades in mice by inactivating the Notch signaling pathway. However, these alleviating effects of ANGPTL4 silencing on mice were negated by the administration of valproic acid, an agonist of the Notch signaling. This paper provides evidence that the ANGPTL4 knockdown shows significant therapeutic effects on AR by improving the Treg/Th17 cell balancing, effects achieved, at least in part, by blocking the Notch signaling pathway. Show less
📄 PDF DOI: 10.1186/s40001-025-03049-6
ANGPTL4
Xu Cao, Mingfan Liu, Dongmei Zou +3 more · 2025 · Discover oncology · Springer · added 2026-04-24
The intrinsic heterogeneity and invasiveness of diffuse gliomas complicate accurate prognosis. Existing approaches are largely constrained by subtype specificity or limited analytical dimensions. To a Show more
The intrinsic heterogeneity and invasiveness of diffuse gliomas complicate accurate prognosis. Existing approaches are largely constrained by subtype specificity or limited analytical dimensions. To address this gap, a multi- dimension-based prognostic framework encompassing the full glioma spectrum was developed, accompanied by an analysis of the associated immune microenvironment. A total of 3,323 glioma samples from the SEER (n = 2181), CGGA (n = 807), and TCGA (n = 335) datasets were integrated. Differentially expressed genes were screened using the limma package, and a Lasso-Cox-based prognostic signature (Glioma-GDPM) was established. Clinical variables such as age, grade, and IDH mutation status were harmonized through propensity score matching to construct a multi-omics prognostic model (Glioma-GCDPM). GSEA, CIBERSORT-based immune infiltration analysis, and TIDE scoring were used to investigate the biological characteristics of different risk subgroups. Eleven key prognostic genes (such as PRAMEF2 and FADS1) and four clinical factors (age, tumor grade, IDH mutation, and 1p/19q codeletion) were identified. Glioma-GCDPM demonstrated favorable predictive ability in both the internal test cohort (AUC 0.81-0.86) and external validation sets (AUC 0.59-0.83). High-risk tumors exhibited greater invasiveness, with significant enrichment in cell cycle and proliferation-associated pathways. Additionally, a suppressed immune microenvironment was observed, reflected by elevated M2 macrophage infiltration and increased T cell dysfunction scores. The multi-omics model established in this study enables precise stratification of prognostic risk in diffuse glioma patients and reveals immunosuppressive features in high-risk individuals, providing a new basis for personalized treatment strategies. Show less
📄 PDF DOI: 10.1007/s12672-025-03551-7
FADS1
Qin Tian, Jinxiang Wang, Qiji Li +16 more · 2025 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Advanced renal cell carcinoma (RCC) primarily relies on targeted and immune-based therapies, yet these treatments often face limitations due to inefficacy and drug resistance. Branched-chain α-keto-ac Show more
Advanced renal cell carcinoma (RCC) primarily relies on targeted and immune-based therapies, yet these treatments often face limitations due to inefficacy and drug resistance. Branched-chain α-keto-acid dehydrogenase kinase (BCKDK) has been implicated in promoting RCC metastasis, but its specific substrates and the mechanisms underlying its regulation of RCC progression remain poorly understood. This study uncovers a novel mechanism whereby BCKDK-mediated AKT phosphorylation drives RCC tumorigenesis and drug resistance. Elevated BCKDK expression correlates with poor prognosis in RCC clinical samples. BCKDK deficiency inhibits RCC cell proliferation and tumorigenesis both in vitro and in vivo. Mechanistic investigations reveal that BCKDK directly binds to and regulates the phosphorylation of AKT. BCKDK-mediated phosphorylation of AKT decreases ubiquitin-mediated AKT protein degradation, and promotes tumorigenesis via activation of the AKT/mTOR signaling pathway. RNA sequencing identifies BCKDK's involvement in the drug metabolism network and apoptotic signaling pathways. The BCKDK/AKT/ABCB1 axis mediates doxorubicin resistance. Targeting BCKDK/AKT inhibits the growth of RCC patient-derived organoids (PDOs), enhances doxorubicin-induced apoptosis in RCC cells, and suppresses tumor growth in vivo. These findings identify a previously unrecognized phosphorylation substrate of BCKDK and highlight the critical role of the BCKDK/AKT signaling axis in RCC progression, offering a promising target for therapeutic intervention. Show less
📄 PDF DOI: 10.1002/advs.202411081
BCKDK
Shuanghui Chen, Yan Lu, Hao Chen +6 more · 2025 · Molecular biology and evolution · Oxford University Press · added 2026-04-24
The Kirgiz, a Turkic-speaking ethnic group with a rich nomadic heritage, represent a pivotal population for understanding human migration and adaptation in Central Asia. However, their genetic origins Show more
The Kirgiz, a Turkic-speaking ethnic group with a rich nomadic heritage, represent a pivotal population for understanding human migration and adaptation in Central Asia. However, their genetic origins and admixture history remain largely unexplored. Here, we present the first comprehensive genomic study of Kirgiz populations from Xinjiang, China (XJ.KGZ, n = 36) and their counterparts in Kyrgyzstan (KRG), integrating genome-wide data of 2,406 global individuals. Our analyses reveal four primary ancestry components in XJ.KGZ: East Asian (41.7%), Siberian (25.6%), West Eurasian (25.2%), and South Asian (7.6%). Despite close genetic affinity (FST = 0.13%), XJ.KGZ and KRG diverged ∼447 years ago, with limited gene flow post-split. A two-wave admixture model elucidates their demographic history: an initial East-West Eurasian mixture ∼2,225 years ago, likely reflecting west-east contacts during the period of the Warring States and the Qin Dynasty, followed by secondary admixture events (∼875 to 425 years ago) linked to historical migrations under Mongol and post-Mongol rule. Local adaptation signatures implicate genes critical for cellular tight junction (e.g. PATJ), pathogen invasion (e.g. OR14I1), and cardiac functions (e.g. RYR2) with allele frequency deviations suggesting ancestry-specific selection. While no classical high-altitude adaptation genes (e.g. EPAS1) showed selection signals, RYR2 and C10orf67-implicated in hypoxia response in Tibetan fauna-displayed Western ancestry bias, hinting at convergent adaptation mechanisms. This study advances our understanding of the genetic makeup and admixture history of the Kirgiz people and provides novel insights into human dispersal in Central Asia. Show less
no PDF DOI: 10.1093/molbev/msaf196
PATJ
Cang Li · 2025 · Bulletin of experimental biology and medicine · Springer · added 2026-04-24
The paper is aimed to screen the target molecules of miR-12 and to further explore the mechanism of GAS5 action in prostate cancer. The expression of GPRC5B in prostate cancer cell lines LNCaP, VCaP, Show more
The paper is aimed to screen the target molecules of miR-12 and to further explore the mechanism of GAS5 action in prostate cancer. The expression of GPRC5B in prostate cancer cell lines LNCaP, VCaP, 22RV1, DU145, and PC3 was measured by quantitative real-time PCR with reverse transcription (RT-qPCR) and variations in GPRC5B expression were analyzed after down-regulating GAS5 or silencing miR-12. CCK8 and plate clone experiments were performed to detect changes in proliferative activity and colony-forming capacity of prostate cancer cells after down-regulating GPRC5B. After transfection of prostate cancer cells with sh-GAS5 and/or miR-12 inhibitor, the changes in GPRC5B expression were evaluated with RT-qPCR and Western blotting. Our results showed that GPRC5B was highly expressed in prostate cancer cell lines. Down-regulating of GAS5 decreased GPRC5B expression, while silencing miR-12 increased it. CCK8 and plate clone experiments showed that expression of GPRC5B increased proliferative activity and clone formation ability of prostate cancer cells. RT-qPCR and Western blotting revealed that miR-12 inhibited the promoting effect of GAS5 on GPRC5B expression. Thus, GPRC5B is directly bound to miR-12. GAS5 promotes proliferation, migration, and invasion of prostate cancer cells and participates in malignant progression of tumors by suppressing miR-12-mediated regulation of GPRC5B expression. Show less
📄 PDF DOI: 10.1007/s10517-026-06539-7
GPRC5B
Xiaona Li, Mei Lu, Xinkun Wang +6 more · 2025 · Frontiers in psychiatry · Frontiers · added 2026-04-24
Despite preclinical evidence for berberine's antidepressant potential, its pharmacological effects remain controversial.This study therefore systematically reviews animal research to clarify its mecha Show more
Despite preclinical evidence for berberine's antidepressant potential, its pharmacological effects remain controversial.This study therefore systematically reviews animal research to clarify its mechanisms and support future clinical trials. We searched PubMed, Embase, Web of Science, Cochrane Library, and OVID for studies on berberine in depression models up to March 20, 2025. Analysis used STATA 15.0 and Review Manager 5.4, with study quality assessed via SYRCLE's risk of bias tool. The meta-analysis included 18 studies (338animals). Overall, berberine significantly reduced depression-like behaviors in animal models.Specifically, BBR increased total locomotor activity in the open field test (SMD=2.79, 95% CI: 1.55, 4.02) and time spent in the center zone (SMD=2.49, 95% CI:1.61, 3.37), reduced immobility time in both the forced swim test and tail suspension test (SMD =-4.42, 95% CI:-5.77,-3.07; SMD=-4.46, 95% CI:-6.21, -2.71), increased sucrose intake in the sucrose preference test (SMD = 3.72, 95% CI: 2.37, 5.07), and reduced feeding latency in the novelty-suppressed feeding test (SMD=-5.72, 95% CI:-7.63, -3.82). However, BBR did not significantly alter the number of square crossings (SMD=1.36, 95%CI:-0.07 , 2.79) or rearing frequency (SMD=1.66, 95% CI: -0.29, 3.61) in the open field test. BBR also increased the levels of body weight, brain-derived neurotrophic factor, dopamine, serotonin, and norepinephrine,while reducing the levels of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Preclinical studies suggest that berberine may represent a promising therapeutic agent for the treatment of depressive disorders. Its antidepressant effects appear to be closely associated with the modulation of neurotransmitter levels,reduction of oxidative stress, and inhibition of inflammatory responses.However, methodological limitations may constrain these findings. Larger, more rigorous preclinical studies are needed for confirmation. https://inplasy.com/inplasy-2025-6-0002, identifier INPLASY202560002. Show less
📄 PDF DOI: 10.3389/fpsyt.2025.1653929
BDNF
Peilu She, Bangjun Gao, Dongliang Li +18 more · 2025 · Nature communications · Nature · added 2026-04-24
Energy deprivation and metabolic rewiring of cardiomyocytes are widely recognized hallmarks of heart failure. Here, we report that HEY2 (a Hairy/Enhancer-of-split-related transcriptional repressor) is Show more
Energy deprivation and metabolic rewiring of cardiomyocytes are widely recognized hallmarks of heart failure. Here, we report that HEY2 (a Hairy/Enhancer-of-split-related transcriptional repressor) is upregulated in hearts of patients with dilated cardiomyopathy. Induced Hey2 expression in zebrafish hearts or mammalian cardiomyocytes impairs mitochondrial respiration, accompanied by elevated ROS, resulting in cardiomyocyte apoptosis and heart failure. Conversely, Hey2 depletion in adult mouse hearts and zebrafish enhances the expression of mitochondrial oxidation genes and cardiac function. Multifaceted genome-wide analyses reveal that HEY2 enriches at the promoters of genes known to regulate metabolism (including Ppargc1, Esrra and Cpt1) and colocalizes with HDAC1 to effectuate histone deacetylation and transcriptional repression. Consequently, restoration of PPARGC1A/ESRRA in Hey2- overexpressing zebrafish hearts or human cardiomyocyte-like cells rescues deficits in mitochondrial bioenergetics. Knockdown of Hey2 in adult mouse hearts protects against doxorubicin-induced cardiac dysfunction. These studies reveal an evolutionarily conserved HEY2/HDAC1-Ppargc1/Cpt transcriptional module that controls energy metabolism to preserve cardiac function. Show less
📄 PDF DOI: 10.1038/s41467-024-55557-4
HEY2
Yuping Zhang, Hengming Zhang, Xiufeng Li · 2025 · Frontiers in oncology · Frontiers · added 2026-04-24
To investigate the clinical and pathological characteristics of patients with non-small cell lung cancer exhibiting coexistence of Clinical data, as well as histopathological, immunohistochemical, and Show more
To investigate the clinical and pathological characteristics of patients with non-small cell lung cancer exhibiting coexistence of Clinical data, as well as histopathological, immunohistochemical, and molecular pathological characteristics, of two patients harboring both Both patients were women aged 57 and 66 years. The two cases were diagnosed as invasive lung adenocarcinoma, and immunohistochemical staining showed that all tumor cells expressed CK7, Napsin A, TTF-1, and PD-L1. In Case 1, an Show less
📄 PDF DOI: 10.3389/fonc.2025.1664782
FGFR1
Feixiang He, Qifang Chen, Peilin Gu +4 more · 2025 · Ophthalmology science · Elsevier · added 2026-04-24
To identify the connections between lipid biomarkers and the anti-VEGF therapy response in patients with neovascular age-related macular degeneration (nAMD). A bidirectional and multivariable Mendelia Show more
To identify the connections between lipid biomarkers and the anti-VEGF therapy response in patients with neovascular age-related macular degeneration (nAMD). A bidirectional and multivariable Mendelian randomization study. The summary statistics for anti-VEGF nAMD treatment response included a total of 128 responders, 51 nonresponders, and 6 908 005 genetic variants available for analysis. The sample size of lipid biomarkers is 441 016 and 12 321 875 genetic variants available for analysis. Two-sample Mendelian randomization (MR) method was conducted to exhaustively appraise the causalities among 13 lipid biomarkers and the risk of different anti-VEGF treatment responses (including visual acuity [VA] and central retinal thickness [CRT]) for nAMD subtypes. Thirteen lipid biomarkers, VA, and CRT. A positive causal relationship was identified between triglycerides (TGs), apolipoproteins (Apos) E2, ApoE3, total cholesterol (TC), and VA response to anti-VEGF therapy in patients with nAMD, as confirmed by MR-Egger, weighted median, and weighted mode models. The MR-Egger model yielded statistically significant results for TC, ApoA-I, ApoB, and ApoA-V in relation to the CRT response to anti-VEGF treatment in patients with nAMD. In the reverse MR, the MR-Egger model identified significant causal relationships between ApoA-I, low-density lipoprotein cholesterol (LDL-c), ApoE3, and ApoF and the VA response. However, this was not the case in the weighted median and weighted mode models. In the MR-Egger model, ApoB, LDL-c, ApoE3, and ApoM were identified as significantly influencing the CRT response. In the multisample MR analysis, TC, high-density lipoprotein cholesterol, LDL-c, and TG were found to be causally related to VA response, and TC was also identified as being causally related to the CRT response to anti-VEGF therapy in patients with nAMD. This MR study suggests unidirectional causality between TG and ApoE3 and the response to anti-VEGF treatment in patients with nAMD. The author(s) have no proprietary or commercial interest in any materials discussed in this article. Show less
📄 PDF DOI: 10.1016/j.xops.2025.100711
APOB
Yao Zheng, Jiajia Li, Haojun Zhu +3 more · 2025 · Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · Elsevier · added 2026-04-24
Studies showed that contaminants adhered to the surface of nano-polystyrene microplastics (NPs) have a toxicological effect. Juveniles tilapia were dispersed into four groups: the control group A, 75  Show more
Studies showed that contaminants adhered to the surface of nano-polystyrene microplastics (NPs) have a toxicological effect. Juveniles tilapia were dispersed into four groups: the control group A, 75 nm NPs exposed group B, 5 ng·L Show less
no PDF DOI: 10.1016/j.cbpc.2024.110117
LPL
Yuwei Liu, Nan Zheng, Huan Chen +3 more · 2025 · Frontiers in psychology · Frontiers · added 2026-04-24
This study aims to identify and characterize daily activity accumulation patterns (bouts of physical activity and sedentary behavior) among adolescents and then to explore the associations between the Show more
This study aims to identify and characterize daily activity accumulation patterns (bouts of physical activity and sedentary behavior) among adolescents and then to explore the associations between these groups and depressive symptoms. A total of 521 adolescents aged 13-18 years from Wuhan and Changsha, China, were included. Bouts of physical activity (PA) and sedentary behavior (SED) were measured using accelerometers. The Center for Epidemiologic Studies Depression Scale was used to assess participants' depressive symptoms. Latent profile analysis was employed to identify distinct groups based on their activity patterns. Three distinct groups were identified: "Prolonged sitters" ( The synergistic effect of strategies to reduce total SED duration by limiting SED bouts to 30 min or less and increasing light physical activity (LPA) may also be effective in alleviating depressive symptoms in adolescents. Show less
📄 PDF DOI: 10.3389/fpsyg.2025.1683685
LPA
Yasuaki Uemoto, Chang-Ching A Lin, Bingnan Wang +10 more · 2025 · Cancer letters · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/j.canlet.2025.217782
FGFR1
Keyan Wang, Haiyu Li, Yong Zhang +2 more · 2025 · Circulation. Cardiovascular imaging · added 2026-04-24
no PDF DOI: 10.1161/CIRCIMAGING.124.017837
MYBPC3
Chongyang Cai, Leipeng Li, Xiaohuan Lv +12 more · 2025 · Nature communications · Nature · added 2026-04-24
Lanthanides-doped luminescent materials have gathered considerable attention due to their application potential in stress sensing, lighting and display, anti-counterfeiting technology and so forth. Ho Show more
Lanthanides-doped luminescent materials have gathered considerable attention due to their application potential in stress sensing, lighting and display, anti-counterfeiting technology and so forth. However, existing materials mainly cover the 380-1540 nm range, with slight extension to the UV region, impeding their applications in solar-blind imaging, background-free tracking, concealed communication, etc. To address this challenge, here we propose guidelines for far-UVC (200-230 nm) optical design. Accordingly, we achieve multi-stimulated far-UVC luminescence at ~222 nm in Pr Show less
📄 PDF DOI: 10.1038/s41467-025-61522-6
LPL
Xiao Li, Xianglong Huang, Keyan Song +5 more · 2025 · Phytomedicine : international journal of phytotherapy and phytopharmacology · Elsevier · added 2026-04-24
Atherosclerosis is the leading cause of cardiovascular disease-related morbidity and mortality. The traditional Chinese medicine Qingre Sanjie Formula (QRSJF), composed of Prunellae Spica, Sargassum, Show more
Atherosclerosis is the leading cause of cardiovascular disease-related morbidity and mortality. The traditional Chinese medicine Qingre Sanjie Formula (QRSJF), composed of Prunellae Spica, Sargassum, Fritillariae Thunbergii Bulbus, Leonuri Herba, and Forsythiae Fructus, has shown efficacy in treating cardiovascular diseases, although its mechanisms are unclear. This study aimed to explore the protective effects of QRSJF against atherosclerosis and the mechanisms involved. The composition of QRSJF was analyzed using Ultra Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry. An 8-week high-fat diet (HFD)-induced atherosclerosis model was established in ApoE Both low- and high-dose QRSJF effectively attenuated dyslipidemia and decreased serum inflammatory cytokine levels in HFD-fed ApoE QRSJF improves dyslipidemia and reduces atherosclerotic plaque in ApoE Show less
no PDF DOI: 10.1016/j.phymed.2025.156691
NR1H3